Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.
Gregory Yoke Hong LipJulius NikorowitschSusanne SehnerNina FluschnikEmanuele BertagliaCarina Blomstrom-LundqvistAxel BrandesVincent BeugerMelanie Jane CalvertAlan John CammGrigoris ChlouverakisGheorghe Andrei DanWolfgang DichtlHans-Christoph DienerAlexander FierenzAndreas GoetteJoris R de GrootAstrid N L HermansAndrzej LubińskiEloi MarijonBela MerkelyLluis MontAnn-Kathrin OzgaKim RajappanAndrea SarkozyDaniel ScherrRenate B SchnabelUlrich SchottenEmmanuel N SimantirakisTobias ToennisPanos E VardasDan WichterleAntonia ZapfPaulus F KirchhofPublished in: European heart journal (2024)
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- study protocol
- left atrial appendage
- direct oral anticoagulants
- phase iii
- venous thromboembolism
- heart failure
- phase ii
- percutaneous coronary intervention
- randomized controlled trial
- coronary artery disease
- metabolic syndrome
- type diabetes
- mitral valve
- open label
- acute coronary syndrome
- insulin resistance